Thus it is likely that ErbB2/ErbB4 pathway is chronically activated in these conditions and its blockage by trastuzumab treatment may empathize trastuzumab-related cardiotoxicity in elder patients with undiagnosed heart diseases. Here, ERBB4 is linked to heart disorder.